Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05620771 · ClinicalTrials.gov registry record · Phase 2
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
A Phase 2 study, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT05620771: Recruiting Phase 2 study, sponsored by Northwestern University.
NCT05620771 is a Phase 2 study that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05620771, a Phase 2 study, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard-of-care treatment with Atezolizumab and Bevacizumab. Treatment with tyrosine kinase inhibitors consists of standard-of-care Lenvatinib or Cabozantinib.
Primary Outcome
To compare PFS by RECIST v1.1 criteria, with Y90 followed by immunotherapy (atezolizumab + bevacizumab, Arm A) or Y90 followed by TKI treatment (lenvatinib or cabozantinib, Arm B). Progression is defined as either radiological progression (with MRI or CT scan) OR clinical progression.
Interventions
- DRUG Y90 + Atezolizumab and Bevacizumab
- DRUG Y90 + TKI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2040-07-01 |
| Phase | Phase 2 |
What NCT05620771 shows while recruiting
NCT05620771 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 2 interventions - of which Y90 + Atezolizumab and Bevacizumab is the first listed.
NCT05620771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05620771 about?
NCT05620771 is a clinical study titled "Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk". The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard-...
What is the current status of trial NCT05620771?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2022-11-30. Estimated completion is 2040-07-01.
What interventions are being tested in trial NCT05620771?
The interventions under investigation include: Y90 + Atezolizumab and Bevacizumab (DRUG), Y90 + TKI (DRUG).
Who is sponsoring clinical trial NCT05620771?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05620771's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI